Personalis (PSNL) Gets a Buy From Lake Street
Needham Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $7
What 5 Analyst Ratings Have To Say About Personalis
Personalis Price Target Maintained With a $7.00/Share by Needham
Craig-Hallum Initiates Personalis(PSNL.US) With Buy Rating, Announces Target Price $8
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $7
BTIG Reaffirms Their Buy Rating on Personalis (PSNL)
Personalis Initiated at Buy by Craig-Hallum
Personalis Analyst Ratings
Craig-Hallum Initiates Coverage On Personalis With Buy Rating, Announces Price Target of $8
Craig Hallum Initiates Coverage on Personalis With Buy Rating, $8 Price Target
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Maintains Target Price $5
Hold Rating for Personalis: Balancing Strong Enterprise Sales and Future Uncertainties
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Cuts Target Price to $7
Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (HRTX), Milestone Pharmaceuticals (MIST) and Personalis (PSNL)
Lake Street Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $9
Personalis Is Maintained at Buy by Needham
Personalis Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Personalis, Maintains $8 Price Target
Citi Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $8